Prostate Cancer Reports



Volume 3 Number 11
November 2015
Home > Prostate Cancer Reports > Volume 3, Year 2015 > Number 11, November

CONTENTS

Overall management

Epidemiology and risk factors

Etiology and pathogenesis

Diagnosis and evaluation

Deferred treatment

Radical prostatectomy

Definitive radiotherapy

Hormonal therapy

Metastatic prostate cancer

Psa-only recurrence after treatment with curative intent

Castration-resistant prostate cancer

Integrative medicine

Prognosis and outcome




OVERALL MANAGEMENT


Meetings

CUAJ Editorial
Prostate Cancer: Summary from ASCO 2015.
Can Urol Assoc J. 2015 Jul-Aug;9(7-8):S162-4. doi: 10.5489/cuaj.3213. Published online August 10, 2015.
Source | Abstract | Full text | Similar articles


Recommendations and guidelines

Advanced prostate cancer

Gillessen S, Fanti S, Omlin A; panelists and authors of APCCC.
Reply to the letter to the editor 'Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015' by Gillessen et al.
Ann Oncol. 2015 Sep 7. pii: mdv360. [Epub ahead of print]
Source | Abstract | Full text | Similar articles


von Eyben F, Kiljunen T, Kangasmaki A, Kairemo K, von Eyben R, Joensuu T.
Management of advanced prostate cancer.
Ann Oncol. 2015 Jul 27. pii: mdv327. [Epub ahead of print]
Source | Abstract | Full text | Similar articles


Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B.
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.
Ann Oncol. 2015 Aug;26(8):1589-604. doi: 10.1093/annonc/mdv257. Epub 2015 Jun 3.
Source | Abstract | Full text | Similar articles

EPIDEMIOLOGY AND RISK FACTORS


Risk factors

Antibiotics

Boursi B, Mamtani R, Haynes K, Yang YX.
Recurrent antibiotic exposure may promote cancer formation - Another step in understanding the role of the human microbiota?
Eur J Cancer. 2015 Aug 31. pii: S0959-8049(15)00805-9. doi: 10.1016/j.ejca.2015.08.015. [Epub ahead of print]
Source | Abstract | Full text | Similar articles


Cigarette smoking

Froehner M, Koch R, Wirth MP.
Re: Malte Rieken, Shahrokh F. Shariat, Luis A. Kluth, et al. Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.05.038.
Eur Urol. 2015 Nov;68(5):e103. doi: 10.1016/j.eururo.2015.08.011. Epub 2015 Aug 28.
Source | Abstract | Full text | Similar articles


Rieken M, Shariat SF.
Reply to Michael Froehner, Rainer Koch, Manfred P. Wirth's Letter to the Editor re: Malte Rieken, Shahrokh F. Shariat, Luis A. Kluth, et al. Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.05.038.
Eur Urol. 2015 Nov;68(5):e104-5. doi: 10.1016/j.eururo.2015.08.012. Epub 2015 Aug 24.
Source | Abstract | Full text | Similar articles


Rieken M, Shariat SF, Kluth LA, Fajkovic H, Rink M, Karakiewicz PI, Seitz C, Briganti A, Roupręt M, Loidl W, Trinh QD, Bachmann A, Pourmand G.
Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy.
Eur Urol. 2015 Dec;68(6):949-56. doi: 10.1016/j.eururo.2015.05.038. Epub 2015 Jun 3.
Source | Abstract | Full text | Similar articles


Taneja SS.
Re: Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy.
J Urol. 2015 Nov;194(5):1285-6. doi: 10.1016/j.juro.2015.08.057. Epub 2015 Aug 15.
Source | Abstract | Full text | Similar articles

ETIOLOGY AND PATHOGENESIS


Santoni M, Piva F, Scarpelli M, Cheng L, Lopez-Beltran A, Massari F, Iacovelli R, Berardi R, Santini D, Montironi R.
The origin of prostate metastases: emerging insights.
Cancer Metastasis Rev. 2015 Sep 12. [Epub ahead of print]
Source | Abstract | Similar articles


Molecular resistance in castration-resistant prostate cancer

Chandrasekar T, Yang JC, Gao AC, Evans CP.
Targeting molecular resistance in castration-resistant prostate cancer.
BMC Med. 2015 Sep 1;13:206. doi: 10.1186/s12916-015-0457-6.
Source | Abstract | Full text | Similar articles


Perner S, Cronauer MV, Schrader AJ, Klocker H, Culig Z, Baniahmad A.
Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer.
Oncotarget. 2015 Jun 29. [Epub ahead of print]
Source | Abstract | Full text | Similar articles


Zhang W, Meng Y, Liu N, Wen XF, Yang T.
Insights into Chemoresistance of Prostate Cancer.
Int J Biol Sci. 2015 Aug 1;11(10):1160-70. doi: 10.7150/ijbs.11439. eCollection 2015.
Source | Abstract | Full text | Similar articles

DIAGNOSIS AND EVALUATION


Clinical diagnosis

Prostate-specific antigen

Neutrophil-to-lymphocyte ratio

Kawahara T, Fukui S, Sakamaki K, Ito Y, Ito H, Kobayashi N, Izumi K, Yokomizo Y, Miyoshi Y, Makiyama K, Nakaigawa N, Yamanaka T, Yao M, Miyamoto H, Uemura H.
Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy.
Oncotarget. 2015 Aug 20. [Epub ahead of print]
Source | Abstract | Full text | Similar articles


Genomic markers

Hong SK.
Genetic classifiers for prostate cancer: A new era on the horizon?
Korean J Urol. 2015 Sep;56(9):605-6. doi: 10.4111/kju.2015.56.9.605. Epub 2015 Aug 31.
Source | Abstract | Full text | Similar articles


Prostate biopsy

Liquid biopsy: circulating tumor cells and circulating tumor DNA

Gingras I, Salgado R, Ignatiadis M.
Liquid biopsy: will it be the 'magic tool' for monitoring response of solid tumors to anticancer therapies?
Curr Opin Oncol. 2015 Nov;27(6):560-7. doi: 10.1097/CCO.0000000000000223.
Source | Abstract | Full text | Similar articles


Role of imaging

Multiparametric MRI

Fütterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, Taneja SS, Thoeny H, Villeirs G, Villers A.
Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature.
Eur Urol. 2015 Feb 2. pii: S0302-2838(15)00036-6. doi: 10.1016/j.eururo.2015.01.013. [Epub ahead of print]
Source | Abstract | Similar articles


Sivaraman A, Sanchez-Salas R.
Re: Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature.
Eur Urol. 2015 Oct;68(4):738. doi: 10.1016/j.eururo.2015.06.033.
Source | Abstract | Full text | Similar articles


Wibmer AG, Vargas HA, Hricak H.
Role of MRI in the diagnosis and management of prostate cancer.
Future Oncol. 2015 Sep 14. [Epub ahead of print]
Source | Abstract | Similar articles


Metabolic imaging

Bombardieri E, Setti L, Kirienko M, Antunovic L, Guglielmo P, Ciocia G.
Which metabolic imaging, besides bone scan with 99mTc-phosphonates, for detecting and evaluating bone metastases in prostatic cancer patients? An open discussion.
Q J Nucl Med Mol Imaging. 2015 Dec;59(4):381-99. Epub 2015 Sep 3.
Source | Abstract | Full text | Similar articles


Prognostic Gleason grade groups

Samaratunga H, Delahunt B, Gianduzzo T, Coughlin G, Duffy D, LeFevre I, Johannsen S, Egevad L, Yaxley J.
The prognostic significance of the 2014 International Society of Urological Pathology (ISUP) grading system for prostate cancer.
Pathology. 2015 Oct;47(6):515-9. doi: 10.1097/PAT.0000000000000315.
Source | Abstract | Similar articles


Histopathology of radical prostatectomy specimens

Radical prostatectomy specimen report

Gleason score upgrade

Alchin DR, Murphy D, Lawrentschuk N.
What Are the Predictive Factors for Gleason Score Upgrade following RP?
Urol Int. 2015 Aug 29. [Epub ahead of print]
Source | Abstract | Full text | Similar articles

DEFERRED TREATMENT


Deferred treatment of localised prostate cancer

Active surveillance

D'Amico AV.
Personalizing the Use of Active Surveillance As an Initial Approach for Men With Newly Diagnosed Prostate Cancer.
J Clin Oncol. 2015 Oct 20;33(30):3365-6. doi: 10.1200/JCO.2015.63.6118. Epub 2015 Aug 31.
Source | Abstract | Full text | Similar articles


Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, Carter HB.
Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer.
J Clin Oncol. 2015 Oct 20;33(30):3379-85. doi: 10.1200/JCO.2015.62.5764. Epub 2015 Aug 31.
Source | Abstract | Full text | Similar articles

RADICAL PROSTATECTOMY


Neoadjuvant and adjuvant hormonal therapy and radical prostatectomy

D'Amico AV.
Is Gleason Grade 5 Prostate Cancer Resistant to Conventional Androgen Deprivation Therapy?
Eur Urol. 2015 Sep 11. pii: S0302-2838(15)00853-2. doi: 10.1016/j.eururo.2015.08.057. [Epub ahead of print]
Source | Abstract | Similar articles

DEFINITIVE RADIOTHERAPY


Radiotherapy for localised prostate cancer

Neoadjuvant or adjuvant hormone therapy plus radiotherapy

Raldow AC, Zhang D, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV.
Short-course androgen deprivation therapy and the risk of death from high-risk prostate cancer in men undergoing external beam radiation therapy and brachytherapy.
Brachytherapy. 2015 Sep 8. pii: S1538-4721(15)00532-2. doi: 10.1016/j.brachy.2015.08.004. [Epub ahead of print]
Source | Abstract | Similar articles


Voog JC, Paulus R, Shipley WU, Smith MR, McGowan DG, Jones CU, Bahary JP, Zeitzer KL, Souhami L, Leibenhaut MH, Rotman M, Husain SM, Gore E, Raben A, Chafe S, Sandler HM, Efstathiou JA.
Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
Eur Urol. 2015 Sep 8. pii: S0302-2838(15)00770-8. doi: 10.1016/j.eururo.2015.08.027. [Epub ahead of print]
Source | Abstract | Similar articles


Neoadjuvant or adjuvant chemotherapy plus radiotherapy

Rosenthal SA, Hunt D, Sartor AO, Pienta KJ, Gomella L, Grignon D, Rajan R, Kerlin KJ, Jones CU, Dobelbower M, Shipley WU, Zeitzer K, Hamstra DA, Donavanik V, Rotman M, Hartford AC, Michalski J, Seider M, Kim H, Kuban DA, Moughan J, Sandler H.
A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.
Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):294-302. doi: 10.1016/j.ijrobp.2015.05.024. Epub 2015 Jul 21.
Source | Abstract | Similar articles

HORMONAL THERAPY


Cost-effectiveness of hormonal therapy options

Du K, Luzny P, Lowrance WT.
Re: Effectiveness of Primary Androgen-Deprivation Therapy for Clinically Localized Prostate Cancer.
Eur Urol. 2015 Oct;68(4):738-9. doi: 10.1016/j.eururo.2015.06.034.
Source | Abstract | Full text | Similar articles


Potosky AL, Haque R, Cassidy-Bushrow AE, Ulcickas Yood M, Jiang M, Tsai HT, Luta G, Keating NL, Smith MR, Van Den Eeden SK.
Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer.
J Clin Oncol. 2014 May 1;32(13):1324-30. doi: 10.1200/JCO.2013.52.5782. Epub 2014 Mar 17.
Source | Abstract | Full text | Similar articles

METASTATIC PROSTATE CANCER


Androgen deprivation therapy

Effect of concomitant pharmaceutical treatment

Jung J, Lee C, Lee C, Kwon T, You D, Jeong IG, Hong JH, Ahn H, Kim CS.
Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer.
Korean J Urol. 2015 Sep;56(9):630-6. doi: 10.4111/kju.2015.56.9.630. Epub 2015 Sep 2.
Source | Abstract | Full text | Similar articles

PSA-ONLY RECURRENCE AFTER TREATMENT WITH CURATIVE INTENT

Post-radical prostatectomy biochemical recurrence

Ün S, Türk H, Koca O, Divrik RT, Zorlu F.
Factors determining biochemical recurrence in low-risk prostate cancer patients who underwent radical prostatectomy.
Turk J Urol. 2015 Jun;41(2):61-6. doi: 10.5152/tud.2015.65624.
Source | Abstract | Full text | Similar articles

CASTRATION-RESISTANT PROSTATE CANCER

Background

Hathaway AR, Baker MK, Sonpavde G.
Emerging agents for the therapy of advanced prostate cancer.
Future Oncol. 2015 Sep 14. [Epub ahead of print]
Source | Abstract | Similar articles


Assessing treatment outcome in castration-resistant PCa (CRPC)

11C-choline PET/CT for evaluating the response to treatment

Ceci F, Castellucci P, Graziani T, Schiavina R, Renzi R, Borghesi M, Di Tullio P, Brunocilla E, Ardizzoni A, Fanti S.
11C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel.
Eur J Nucl Med Mol Imaging. 2015 Sep 1. [Epub ahead of print]
Source | Abstract | Similar articles


First-line treatment of mCRPC

Maroto P, Solsona E, Gallardo E, Mellado B, Morote J, Arranz JÁ, Gómez-Veiga F, Unda M, Climent MÁ, Alcaraz A.
Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer.
Crit Rev Oncol Hematol. 2015 Aug 1. pii: S1040-8428(15)30011-1. doi: 10.1016/j.critrevonc.2015.07.011. [Epub ahead of print]
Source | Abstract | Full text | Similar articles


Second-line treatment of mCRPC

Dreicer R.
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
Clin Adv Hematol Oncol. 2015 May;13(5):293-5.
Source | Abstract | Full text | Similar articles


Li J, Armstrong AJ.
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
Clin Adv Hematol Oncol. 2015 May;13(5):293-8.
Source | Abstract | Full text | Similar articles


Novel agents

Caffo O, Maines F, Veccia A.
Reply to Kevin Lu's Letter to the Editor re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.
Eur Urol. 2015 Dec;68(6):e132-3. doi: 10.1016/j.eururo.2015.08.018. Epub 2015 Aug 28.
Source | Abstract | Full text | Similar articles


Caffo O, De Giorgi U, Fratino L, Alesini D, Zagonel V, Facchini G, Gasparro D, Ortega C, Tucci M, Verderame F, Campadelli E, Lo Re G, Procopio G, Sabbatini R, Donini M, Morelli F, Sartori D, Zucali P, Carrozza F, D'Angelo A, Vicario G, Massari F, Santini D, Sava T, Messina C, Fornarini G, La Torre L, Ricotta R, Aieta M, Mucciarini C, Zustovich F, Macrini S, Burgio SL, Santarossa S, D'Aniello C, Basso U, Tarasconi S, Cortesi E, Buttigliero C, Ruatta F, Veccia A, Conteduca V, Maines F, Galligioni E.
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study.
Eur Urol. 2015 Jul;68(1):147-53. doi: 10.1016/j.eururo.2014.10.014. Epub 2014 Oct 25.
Source | Abstract | Similar articles


Crona DJ, Milowsky MI, Whang YE.
Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
Clin Pharmacol Ther. 2015 Sep 1. doi: 10.1002/cpt.256. [Epub ahead of print]
Source | Abstract | Similar articles


Dogan M, Erdem GU, Zengin N.
Is it Time to Change the Control Placebo Arms in Phase III Trials of Metastatic Castration Resistant Prostate Cancer?
Asian Pac J Cancer Prev. 2015;16(14):6167-9.
Source | Abstract | Full text | Similar articles


Lu K.
Re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.
Eur Urol. 2015 Dec;68(6):e129-31. doi: 10.1016/j.eururo.2015.08.017. Epub 2015 Aug 28.
Source | Abstract | Full text | Similar articles


Maines F, Caffo O, Veccia A, Trentin C, Tortora G, Galligioni E, Bria E.
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer.
Crit Rev Oncol Hematol. 2015 Aug 1. pii: S1040-8428(15)30013-5. doi: 10.1016/j.critrevonc.2015.07.013. [Epub ahead of print]
Source | Abstract | Full text | Similar articles


Bone targeted therapies

Common complications due to bone metastases

Denosumab

Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Martín M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A.
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.
Support Care Cancer. 2015 Sep 3. [Epub ahead of print]
Source | Abstract | Full text | Similar articles

INTEGRATIVE MEDICINE


Dietary, nutritional, and physical activity interventions

Systematic reviews

Hackshaw-McGeagh LE, Perry RE, Leach VA, Qandil S, Jeffreys M, Martin RM, Lane JA.
A systematic review of dietary, nutritional, and physical activity interventions for the prevention of prostate cancer progression and mortality.
Cancer Causes Control. 2015 Nov;26(11):1521-50. doi: 10.1007/s10552-015-0659-4. Epub 2015 Sep 9.
Source | Abstract | Full text | Similar articles

PROGNOSIS AND OUTCOME


Prognostic effect of concomitant pharmaceutical treatment

Statins

Luo Y, She DL, Xiong H, Fu SJ, Yang L.
The Prognostic Effect of Statin Use on Urologic Cancers: An Updated Meta-Analysis of 35 Observational Studies.
Medicine (Baltimore). 2015 Sep;94(36):e1523. doi: 10.1097/MD.0000000000001523.
Source | Abstract | Full text | Similar articles


Risk of biochemical recurrence after radical prostatectomy

High grade (Gleason score 8-10) prostate cancer

Fischer S, Lin D, Simon RM, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ, Vidal AC.
Do all men with pathological Gleason score 8-10 prostate cancer have poor outcomes? Results from the SEARCH database.
BJU Int. 2015 Sep 9. doi: 10.1111/bju.13319. [Epub ahead of print]
Source | Abstract | Similar articles